Zika virus mrna vaccines
AssigneeModernaTX, Inc.
InventorsGiuseppe Ciaramella, Sunny Himansu
Life of this patent
Estimating the term…
Abstract
Provided herein, in some embodiments, are Zika virus RNA vaccines and methods of producing an antigen-specific immune response in a subject.
Claims26
A method comprising administering to a subject an immunogenic composition comprising a messenger ribonucleic acid (mRNA) that comprises an open reading frame (ORF) encoding a JEV signal peptide fused to a Zika virus (ZIKV) prME protein formulated in a lipid nanoparticle in an effective amount to induce in the subject a ZIKV prME-specific immune response, wherein the ORF comprises the sequence of SEQ ID NO:
- 1.
-38. (canceled)
The method of claim 55, wherein the ionizable cationic lipid comprises the following compound:
A method comprising administering to a subject an immunogenic composition comprising a messenger ribonucleic acid (mRNA) that comprises a 5′ UTR, an open reading frame (ORF) encoding a JEV signal peptide fused to a Zika virus (ZIKV) prME protein, and a 3′ UTR formulated in a lipid nanoparticle in an effective amount to induce in the subject a ZIKV prME-specific immune response, wherein the JEV signal peptide comprises the sequence of SEQ ID NO:18, the 5′ UTR comprises the sequence of SEQ ID NO:13, and the 3′UTR comprises the sequence of SEQ ID NO:15.
An immunogenic composition comprising a messenger ribonucleic acid (mRNA) vaccine comprising a 5′ untranslated region (UTR), an open reading frame (ORF) encoding a JEV signal peptide fused to a Zika virus (ZIKV) prME protein, and a 3′ UTR, formulated in a lipid nanoparticle.
Dependencies are inferred from the claim text.